Literature DB >> 19513317

Neurocutaneous melanosis presenting as chronic partial epilepsy.

Byoung Seok Ye1, Yang-Je Cho, Sang Hyun Jang, Byung In Lee, Kyoung Heo, Hyun Ho Jung, Jin Woo Chang, Se Hoon Kim.   

Abstract

BACKGROUND: Neurocutaneous melanosis (NCM) is a rare neurocutaneous syndrome characterized by the presence of multiple congenital melanocytic nevi (CMN) and the proliferation of melanocytes in the central nervous system, usually involving the leptomeninges. Chronic partial epilepsy as a sole manifestation is rare in NCM. CASE REPORT: A 32-year-old man suffering from chronic partial epilepsy presented with multiple CMN on his trunk and scalp. Brain MRI demonstrated a focal lesion in the right amygdala that was consistent with interictal epileptiform discharges in the right temporal region on electroencephalography (EEG). An anterior temporal lobectomy was performed, and the pathology investigation revealed numerous melanophages in the amygdala. The patient was seizure-free after surgery.
CONCLUSIONS: We report a patient with NCM presenting as chronic partial epilepsy who was successfully treated by anterior temporal lobectomy.

Entities:  

Keywords:  Epilepsy surgery; Neurocutaneous melanosis; Partial epilepsy

Year:  2008        PMID: 19513317      PMCID: PMC2686876          DOI: 10.3988/jcn.2008.4.3.134

Source DB:  PubMed          Journal:  J Clin Neurol        ISSN: 1738-6586            Impact factor:   3.077


Introduction

Neurocutaneous melanosis (NCM) is a rare congenital, noninheritable neurocutaneous syndrome, characterized by the presence of large and/or multiple congenital melanocytic nevi (CMN) associated with melanosis or melanoma that usually appear in the leptomeninges. Although the clinical presentations of NCM vary with age, NCM is generally accompanied by significant neurological deficits. However, NCM as a cause of epilepsy without any neurological deficit is extremely rare. We report a case of chronic partial epilepsy caused by pathologically proven parenchymal NCM in the brain without leptomeningeal involvement, that was successfully treated surgically.

Case Report

A 32-year-old right-handed man visited our epilepsy clinic due to drug-resistant partial epilepsy. His seizures started at the age of 22 years, since when he had suffered from frequent episodes of disgusting odor and light-headedness despite antiepileptic drug treatment. Also, he had occasionally experienced motionless staring followed by generalized tonic-clonic seizures when he had not complied with treatment. His familial and own medical histories were not remarkable, and the findings of a neurological examination were normal. Electroencephalography (EEG) showed frequent right temporal sharp waves with maximal negativity in the ipsilateral nasopharyngeal electrode. Brain MRI showed a small focal lesion in the lateral part of the right amygdala. The lesion was hyperintense on a T2-weighted image and hypointense on a T1-weighted image without gadolinium enhancement (Fig. 1), which suggested a benign tumor.1 There were multiple large black pigmented nevi on the back, scalp, and posterior neck area, which had existed from birth. The largest black nevus was on his back, covering 9% of his body surface area (1.82 m2).
Fig. 1

Brain MRI. T2-weighted images (A, B), and T1-weighted gadolinium-enhancement images (C, D) show a focal lesion (arrow head) with hyperintensity and hypointensity without enhancement in the right amygdala, respectively.

The right temporal lobe including the amygdaloid lesion was excised. Intraoperative electrocorticography before resection revealed active spikes around the lesion. The amygdala lesion was a grayish-to-black friable soft tissue without definite mass formation. There was no meningeal melanosis. The pathology investigation of the lesion demonstrated numerous melanophages. The skin biopsy of the scalp lesion showed that it was an intradermal nevus, as expected (Fig. 2). He was seizure-free (including aura) during the 15-month postsurgery follow-up period.
Fig. 2

Photograph showing the gross operative finding (A) of a grayish-to-black friable soft tissue without definite mass formation in the right amygdala. The specimen from the lesion (B) contained numerous melanophages in the cortex, which is consistent with neurocutaneous melanosis. The specimen from the scalp nevus (C, D) was compatible with intradermal nevus. Hematoxylin and eosin staining. Scale bars=50 µm.

Discussion

Kadonaga and Frieden2 proposed the following criteria in 1991 that are currently used to diagnose NCM: 1) large and/or multiple CMN in association with meningeal melanosis or melanoma; 2) no evidence of cutaneous melanoma, except in patients with histologically benign meningeal lesions; and 3) no evidence of meningeal melanoma, except in patients with histologically benign cutaneous lesions. The second and third definitions exclude the possibility of metastases from the skin to the central nervous system (CNS) and vice versa, respectively. CMN are classified into large, medium, and small nevi according to their size:3 larger than 20 cm in an adult, 1.5 to 19.9 cm, and smaller than 1.5 cm, respectively. The term "multiple" is used when more than three lesions are present. Kadonaga and Freiden2 found that 66% of NCM patients had large nevi, and the remaining 34% had numerous pigmented lesions in the absence of a single large congenital melanocytic nevus. In their study, all NCM patients had either posterior midline nevi or head and neck lesions, which suggests that the posterior axial distribution is an important risk factor for developing NCM. Our patient also had multiple medium-sized CMN with a posterior axial distribution. Embryologically, melanocytes originate from the neural crest and migrate to various sites in the body, such as the basal layer of the epidermis, pia mater, leptomeninges, medullary reticular formation, and substantia nigra of the midbrain.4 It is thought that CMN and NCM are caused by the arrest or aberrancy of this normal developmental pattern. In NCM, pigmented thickening of the leptomeninges is most frequent in areas with melanocytes.4 Parenchymal melanosis is less common than leptomeningeal melanosis, and caused by primary involvement of the melanin-containing macrophages and melanocytes, or secondary spread via Virchow-Robin spaces from the leptomeninges. The pathology investigation of our patient showed melanin-containing macrophages, and revealed parenchymal melanosis without leptomeningeal melanosis. The neurological manifestations of NCM vary with age.2 Before the age of 2 years, the most common initial clinical signs and symptoms of NCM are related to increased intracranial pressure, including headache (35%), vomiting (42%), generalized seizures (48%), increased head circumference (23%), cranial nerve palsies (26%; in particular VI), papilledema (10%), and meningeal signs (3%).6 The subset of patients with a discrete intracranial mass becomes symptomatic when older (mean age, 12.8 years; range, from birth to 65 years) and is more likely to develop focal seizures, localized sensorimotor deficits, difficulties with speech, or psychiatric symptoms.6 Our patient became symptomatic with partial seizures when he was 22 years old. The prognosis of symptomatic NCM is poor. Most of the 33 NCM patients in a study involving giant CMN7 demonstrated the first neurologic symptom when they were younger than 5 years. Eighty-two percent of the patients died by the time of reporting, and the median age at death was 3 years. However, most of the patients had diffuse leptomeningeal involvement or melanoma. While symptomatic NCM is estimated to occur in less than 3% of patients with giant CMN,7 one study found MRI evidence of CNS melanosis in 10 (23%) of 42 asymptomatic giant-CMN patients,8 among whom only 1 had subsequently developed symptomatic disease during an average follow-up of 5 years. Because the MRI findings of these 10 patients showed parenchymal NCM without diffuse leptomeningeal involvement, the prognosis of parenchymal NCM appears to be much better than that of typical NCM with diffuse leptomeningeal involvement or melanoma. Our patient with parenchymal melanosis subsequently developed epilepsy without neurological deficits. Melanin pigment is inherently paramagnetic, and hence melanin deposits in NCM show a high signal intensity on T1-weighted MRI and a low signal intensity on T2-weighted MRI. This pattern of parenchymal melanosis appears to be most evident and frequent at the amygdala and adjacent anterior temporal cortex.8 In our patient, brain MRI showed the typical location but an atypical pattern of hyperintensity on T2-weighted images and isointensity on T1-weighted images. NCM appears to be a rare cause of chronic partial epilepsy. Some cases with chronic epilepsy related to NCM have been reported, but most of them had other conditions such as CNS melanoma, mental retardation, psychosis, and diffuse leptomeningeal involvement with neurologic deficits.9 To our knowledge, the only surgical case with NCM similar to our patient was a 29-year-old woman with normal psychomotor development and intelligence who had right temporal-lobe epilepsy due to amygdaloid melanosis and underwent right temporal resection.10 Here we have reported a surgically successful case of chronic partial epilepsy caused by pathologically proven parenchymal NCM without leptomeningeal involvement. Therefore, NCM occurring in the brain parenchyma should be considered as a cause of chronic partial epilepsy.
  10 in total

1.  NEURO-CUTANEOUS MELANOSIS.

Authors:  H FOX; J L EMERY; R A GOODBODY; P O YATES
Journal:  Arch Dis Child       Date:  1964-10       Impact factor: 3.791

2.  Neurocutaneous melanosis and epilepsy surgery.

Authors:  Frederick Andermann
Journal:  Epileptic Disord       Date:  2005-03       Impact factor: 1.819

Review 3.  Congenital melanosis: an update.

Authors:  Dominic F Heffel; Seth Thaller
Journal:  J Craniofac Surg       Date:  2005-09       Impact factor: 1.046

4.  Cerebral mass due to neurocutaneous melanosis: eight years later.

Authors:  J V Schaffer; J M McNiff; J L Bolognia
Journal:  Pediatr Dermatol       Date:  2001 Sep-Oct       Impact factor: 1.588

5.  Giant congenital melanocytic nevi: the significance of neurocutaneous melanosis in neurologically asymptomatic children.

Authors:  R D Foster; M L Williams; A J Barkovich; W Y Hoffman; S J Mathes; I J Frieden
Journal:  Plast Reconstr Surg       Date:  2001-04-01       Impact factor: 4.730

6.  An unusual case of neurocutaneous melanosis.

Authors:  Daniela Oliveira de Andrade; Charlotte Dravet; Charles Raybaud; Dominique Broglin; Virginie Laguitton; Nadine Girard
Journal:  Epileptic Disord       Date:  2004-09       Impact factor: 1.819

Review 7.  Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis.

Authors:  M DeDavid; S J Orlow; N Provost; A A Marghoob; B K Rao; Q Wasti; C L Huang; A W Kopf; R S Bart
Journal:  J Am Acad Dermatol       Date:  1996-10       Impact factor: 11.527

Review 8.  Neurocutaneous melanosis: definition and review of the literature.

Authors:  J N Kadonaga; I J Frieden
Journal:  J Am Acad Dermatol       Date:  1991-05       Impact factor: 11.527

9.  MR of parenchymal neurocutaneous melanosis.

Authors:  A Demirci; Y Kawamura; G Sze; C Duncan
Journal:  AJNR Am J Neuroradiol       Date:  1995-03       Impact factor: 3.825

10.  Role of neuroimaging in the presurgical evaluation of epilepsy.

Authors:  Tim Wehner; Hans Lüders
Journal:  J Clin Neurol       Date:  2008-03-20       Impact factor: 3.077

  10 in total
  2 in total

1.  Neurocutaneous melanocytosis (melanosis).

Authors:  Martino Ruggieri; Agata Polizzi; Stefano Catanzaro; Manuela Lo Bianco; Andrea D Praticò; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2020-10-13       Impact factor: 1.475

2.  Neuropathology of neurocutaneous melanosis: histological foci of melanotic neurones and glia may be undetectable on MRI.

Authors:  Veronica A Kinsler; Simon M L Paine; Glenn W Anderson; D Saraji Wijesekara; Neil J Sebire; Wui K Chong; William Harkness; Sarah E Aylett; Thomas S Jacques
Journal:  Acta Neuropathol       Date:  2012-03       Impact factor: 17.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.